Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

Alain C. Mita(Cedars-Sinai Medical Center), Francis J. Giles(National University of Ireland), Steffan T. Nawrocki(University of Arizona), Monica Mita(Novartis (Switzerland))

Clinical Cancer Research

August 12, 2008

10.1158/1078-0432.ccr-08-0746

Cited by 782

Related Papers

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

|Journal of Clinical Oncology|2005|951

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

|Blood|2006|691

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

|Cancer|2006|607

Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance

|Blood|2007|485

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

|Journal for ImmunoTherapy of Cancer|2018|468